Clinical trial · Observational
LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID)
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members. The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Covid-19 | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- lung cancer+COVID-19
- description
- lung cancer patients diagnosed with COVID-19
Primary outcomes (4)
- measure
- Clinical data of lung cancer patients with COVID-19 diagnoses
- timeFrame
- From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years
- description
- Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.
- measure
- Diagnosis data
- timeFrame
- From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years
- description
- Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with lung cancer * Patients who have contracted COVID-19 infection Exclusion Criteria: * Patients diagnosed with lung cancer but no confirmation of COVID-19 infection.
References
Publications (1)
- DERIVEDGonzalez-Cao M, Puertolas T, Martinez-Vila C, Carrera C, Maldonado Seral C, Rodriguez-Jimenez P, Sequero S, Cerezuela-Fuentes P, Feltes Ochoa R, Munoz E, Antonanzas Basa M, Martin-Liberal J, Soria A, Francisco Rodriguez Moreno J, Marquez-Rodas I, Lopez Criado P, Luis Manzano J, Lopez-Castro R, Ayala de Miguel P, Villalobos L, Martin Algarra S, Gonzalez-Barrallo I, Boada A, Garcia Castano A, Puig S, Crespo G, Luna Fra P, Aguayo Zamora C, Feito Rodriguez M, Valles L, Drozdowskyj A, Gardeazabal J, Antonio Fernandez-Morales L, Rodrigo A, Cruz R, Yelamos O, Rubio B, Mujica K, Provencio M, Berrocal A; Spanish Melanoma Group (GEM). SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry. Clin Transl Oncol. 2023 Mar;25(3):768-775. doi: 10.1007/s12094-022-02985-7. Epub 2022 Dec 24. PMID 36566266